Single center experience of urinary bladder malignancy: a 10-year retrospective analysis of hospital data
DOI:
https://doi.org/10.18203/2349-2902.isj20173103Keywords:
Irritative voiding, Neoadjuvant chemotherapy, Radical cystectomy, Transurethral resection of bladder tumorAbstract
Background: Albeit the EAU, NCCN and AUA guidelines provide an excellent evidence-based protocol for the management of MIBC and NMIBC, these guidelines differ with respect to critical issues such as risk level definitions and management strategies. The NE part of the country has always bore the brunt of heavy oncological catastrophe like urinary bladder carcinoma related to extensive tobacco and pesticide usage. MIBC treatment usually encompasses RC with AC/NAC (Level I evidence for NAC use in MIBC exist) but the majority of patients seen at our center have already progressed to advanced stage at presentation and could not undertake full treatment.
Methods: Cancer registry of the last 10 yrs at Dept. of Urology and Renal Transplant Gauhati Medical College Hospital was searched for demographic, clinical, pathological and prognostic data and results summarized using statistical parameters of univariate analysis.
Results: There were a total of 168 patients in the NMIBC group with a majority in the 60-70-year age group. The most common grade was G2 and all DM type 2 and CKD were significantly associated in all the patients analyzed. Chemical exposure in the form of pesticide and smoking was a constant phenomenon in all patients of NMIBC and MIBC (n=66) population. CKD was significantly associated in the MIBC population along with positive urine cytology.
Conclusions: Despite a paucity of high level evidence regarding the majority of management topics in Urinary Bladder cancer in NE part of the country, there was general agreement among the various guideline panels and management guidelines at our institution. Identification of the upfront clinical parameters suggesting severity of disease and time to progression are the two most important domains which will decide the future of UB carcinoma treatment in this part of the world. Categories of evidence synthesized and grades of recommendations will have to be constantly gazed upon to modify and enhance treatment strategies.
References
Stein JP, Lieskovsky G, Cote R Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19;666-75.
Gschwend JE, Fair WR, Vieweg J. Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies Eur Urol. 2000;38:121-30.
Konety BR, Allareddy V, Herr H. Complications after radical cystectomy: analysis of population-based data. Urol. 2006;68:58-64.
Yu RG, Stein JP, Cai J. Superficial (pT2a) and deep/pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol. 2006;176:493-9.
Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177:437-43.
Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al. The urologic diseases in america project. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117:5392-401.
Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF. Predictors of intra-vesical therapy for non-muscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol. 2008;180:520-24.
Gontero P, Oderda M, Altieri V. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the Vesical Antiblastic Therapy Italian Study. Urol Int. 2011;86:19-24.
Singer S, Ziegler C, Schwalenberg T, Hinz A, Gotze H, Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21:1383-93.
Gerharz EW, Mansson A, Mansson W. Quality of life in patients with bladder cancer. Urol Oncol. 2005;23:201-7.
Yoshimura K, Utsunomiya N, Ichioka K, Matsui Y, Terai A, Arai Y. Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urol. 2005;65:290-4.
Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, et al. Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst. 2009;101:860-8.
Muezzinoglu T, Ceylan Y, Temeltas G, Lekili M, Buyuksu C. Evaluation of pain caused by urethrocystoscopy in patients with superficial bladder cancer: a perspective of quality of life. Onkologie 2005;28:260-4.
Abbona A, Morabito F, Rossi R, Billia M, Liberale F, Ferrando U. Quality of life in patients undergone oncopreventive intravesicaltreatment for superficial bladder cancer. Arch Ital Urol Androl. 2007;79:143-6.
Sighinolfi MC, Micali S, De SS, Mofferdin A, Ferrari N, Giacometti M, et al. Bacille Calmette-Guerin intravesical instillation and erectile function: is there a concern? Androl. 2007;39:51-4.
Wei L, Li Q, Liang H, Jianbo L. The quality of life in patients during intravesical treatment and correlation with local symptoms. J Chemother. 2014;26:165-8.
Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, et al. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with non-muscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190:857-62.
Koga H, Ozono S, Tsushima T, Tomita K, Horiguchi Y, Usami M, et al. Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo strain study group. Int J Urol. 2010;17:759-66.
A study on the harmful effects of pesticides used in the cultivation of brinjal in Longai river valley, Karimganj, Assam, India. Assam Univ J Sci Tech Biol Enviro Sci. 2011;7(I):84-8.
Manoharan M, Ayyathurai R, Soloway MS. Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU Int 2009;104:1227-32.
Silverman DT, Devesa SS, Moore LE, Rothman N. Bladder Cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer Epidemiology and Prevention. Third ed. New York, New York: Oxford University Press; 2006:1101-12.
Colt JS, Baris D, Stewart P. Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control. 2004;15(8):759-69.
Dryson E, Mannetje A, Walls C. Case-control study of high risk occupations for bladder cancer in New Zealand. Int J Cancer. 2008;122(6):1340-6.
Samanic CM, Kogevinas M, Silverman DT. Occupation and bladder cancer in a hospital-based case-control study in Spain. Occup Environ Med. 2008;65(5):347-53.
Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294-9.
Vital signs: current cigarette smoking among adults aged >or=18 years: United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(35):1135-40.
Brennan P, Bogillot O, Cordier S. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer. 2000;86(2):289-94.
D'Avanzo B, La Vecchia C, Negri E, Decarli A, Benichou J. Attributable risks for bladder cancer in northern Italy. Ann Epidemiol. 1995;5(6):427-31.
Hartge P, Silverman D, Hoover R. Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst. 1987;78(6):1119-25.
Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990;82(20):1636-40.
Puente D, Hartge P, Greiser E, Cantor KP, King WD, González CA, et al. A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women. Cancer Causes Control. 2006;17(1):71-9.
Vaughn DJ. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium. Cancer Treat. Rev. 2008;34:328-38.
Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506-13.
